TIDMABH

RNS Number : 8979F

Angel Biotechnology Holdings Plc

21 June 2012

21 June 2012

Angel Biotechnology Holdings plc

("Angel" or "the Company")

Notice of Annual General Meeting

Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, announces that the Company's Annual General Meeting will be held at 10am on 12th July 2012 at the offices of Grant Thornton UK LLP, 30 Finsbury Square, London EC2A 1AG.

Copies of the Annual Report and Accounts for the period ended 31 March 2012 have been distributed to shareholders, together with the Notice of Annual General Meeting and form of proxy.

An electronic copy of the Annual Report and Accounts 2012 is available from the Company's website at www.angelbio.com

For further information:

Angel Biotechnology Holdings plc

Lorna Peers, Finance Director +44 (0) 131 445 6077

Stewart White, Acting CEO/Commercial Director www.angelbio.com

Grant Thornton, Corporate Finance

Colin Aaronson / Melanie Frean +44 (0) 20 7383 5100

Hybridan LLP (Broker)

Claire Noyce, Deepak Reddy +44 (0) 20 7947 4350

Media enquiries:

The Communications Portfolio Ltd

Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029

ariane.comstive@communications-portfolio.co.uk

Notes to Editors:

Angel Biotechnology Holdings plc is a full service contract bio-manufacturing partner to biotechnology and pharmaceutical companies worldwide. Angel specialises in advanced biologics including biopharmaceutical proteins and cell therapies, such as cellular vaccines and stem cells. At present, Angel's products are principally used in pre-clinical studies and clinical trials with a view to becoming the contract manufacturer of choice on a continuing basis.

Drug development companies outsource their biopharmaceutical manufacturing requirements to Angel to reduce their own capital requirements and enable them to develop products more rapidly. In addition, Angel provides complete regulatory services and documentation to its customers while its manufacturing processes adhere to the most stringent regulatory requirements. Products are produced to current Good Manufacturing Practice (cGMP) standards as required by the US Food and Drug Administration (FDA), and in facilities that are certified to European standards by the Medicines and Healthcare products Regulatory Agency (MHRA).

Its customers range from early-stage biotechnology companies including ReNeuron plc and US-based Pathfinder Cell Therapy, to established pharmaceutical companies such as Russian-based Materia Medica Holdings.

Angel has three facilities: Pentlands Science Park near Edinburgh where it employs 38 people, a site in Cramlington, near Newcastle-upon-Tyne, which is expected to employ up to 10 people by the end of 2012 and Angel Biomedical Ltd facility in Glasgow.

More information is available at www.angelbio.com .

- Ends -

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOABKDDQNBKDKAB

Angel Biotechnology (LSE:ABH)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024 Plus de graphiques de la Bourse Angel Biotechnology
Angel Biotechnology (LSE:ABH)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024 Plus de graphiques de la Bourse Angel Biotechnology